The anterior saphenous vein. Part 3. Systematic review of the literature and payor coverage policies. Endorsed by the American Vein and Lymphatic Society, the American Venous Forum and the International Union of Phlebology.
Rachel Drgastin, Edward M Boyle, Nicos Labropoulos, Alberto Caggiati, Antonios Gasparis, Suat Doganci, Mark Meissner
{"title":"The anterior saphenous vein. Part 3. Systematic review of the literature and payor coverage policies. Endorsed by the American Vein and Lymphatic Society, the American Venous Forum and the International Union of Phlebology.","authors":"Rachel Drgastin, Edward M Boyle, Nicos Labropoulos, Alberto Caggiati, Antonios Gasparis, Suat Doganci, Mark Meissner","doi":"10.1177/02683555231223281","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to systemically review the literature on Anterior Saphenous Vein (ASV) reflux treatment and insurance impediments to treatment coverage.</p><p><strong>Methods: </strong>A literature search was performed using a PRISMA framework. In addition, a cross-sectional analysis of insurance policies for ASV treatment was evaluated.</p><p><strong>Results: </strong>Published evidence and treatment considerations in the literature for ASV treatment are discussed. In 155 of 226 (68.6%) insurance policies reviewed coverage of ASV ablation was allowed while 62/226 (27.4%) did not specify coverage and 9/226 (4.0%) specified ASV treatment was not covered. Of the 155 that provide ASV coverage, 98 (62.2%) provide coverage with criteria such as requiring prior treatment of the great saphenous vein.</p><p><strong>Conclusions: </strong>Vein treatment experts should continue to advocate to insurance carriers to update their varicose vein treatment policies to reflect the substantial clinical evidence so that patients with ASV reflux can be appropriately treated.</p>","PeriodicalId":94350,"journal":{"name":"Phlebology","volume":" ","pages":"325-332"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11129522/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02683555231223281","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The objective of this study is to systemically review the literature on Anterior Saphenous Vein (ASV) reflux treatment and insurance impediments to treatment coverage.
Methods: A literature search was performed using a PRISMA framework. In addition, a cross-sectional analysis of insurance policies for ASV treatment was evaluated.
Results: Published evidence and treatment considerations in the literature for ASV treatment are discussed. In 155 of 226 (68.6%) insurance policies reviewed coverage of ASV ablation was allowed while 62/226 (27.4%) did not specify coverage and 9/226 (4.0%) specified ASV treatment was not covered. Of the 155 that provide ASV coverage, 98 (62.2%) provide coverage with criteria such as requiring prior treatment of the great saphenous vein.
Conclusions: Vein treatment experts should continue to advocate to insurance carriers to update their varicose vein treatment policies to reflect the substantial clinical evidence so that patients with ASV reflux can be appropriately treated.
研究目的本研究的目的是系统回顾有关大隐静脉前段（ASV）回流治疗和治疗保险障碍的文献：方法：采用 PRISMA 框架进行文献检索。此外，还对 ASV 治疗的保险政策进行了横截面分析评估：结果：讨论了文献中已发表的 ASV 治疗证据和治疗注意事项。在所审查的 226 份保险单中，有 155 份（68.6%）允许 ASV 消融治疗，62/226（27.4%）份未明确说明承保范围，9/226（4.0%）份明确说明不承保 ASV 治疗。在 155 家承保 ASV 的保险公司中，有 98 家（62.2%）的承保标准要求事先治疗大隐静脉：静脉治疗专家应继续倡导保险公司更新其静脉曲张治疗政策，以反映大量临床证据，从而使 ASV 回流患者得到适当的治疗。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
